CompanyDrug

Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria

CompanyDeals

AbbVie Partners with BigHat Biosciences to Develop Next-Gen Antibodies for Oncology and Neuroscience

Company

J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth

CompanyDrug

China Medical System’s Methotrexate Injection Receives NMPA Review for Rheumatoid Arthritis Indication

CompanyMedical Device

Sinocare Inc’s Blood Glucose Monitoring System Earns US FDA Approval

CompanyDrug

Huadong Medicine Gets NMPA Green Light for Sirolimus Real-World Study in Pediatric Epilepsy

CompanyDrug

Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038

CompanyDrug

Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug

CompanyDrug

Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab

CompanyDrug

China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval

CompanyDrug

Ascletis Pharma’s Denifanstat Advances to Phase III for Severe Acne Vulgaris Treatment

CompanyMedical Device

Sino Medical Secures Market Approval in Taiwan for NC Rockstar Coronary Catheter